Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 9, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of Human Endogenous Retroviruses (HERVs) and gut bacteria in children with certain health conditions. HERVs are ancient bits of genetic material that have been in our DNA for a long time and may help control how our immune system works. The researchers want to see if there is a link between the expression of these HERVs and the symptoms experienced by children with Kawasaki Disease, a type of blood vessel inflammation, as well as other illnesses like SARS-CoV-2 infection and certain types of vasculitis. They are also examining whether specific types of bacteria in the gut may influence these health issues.
To participate in this study, children who are newly diagnosed with Kawasaki Disease, vasculitis, SARS-CoV-2 infection, or febrile virosis (a fever-causing illness) are eligible. There are no specific exclusions, making it open for many pediatric patients. Participants can expect to contribute to important research that may lead to new ways to treat and care for children facing these diseases. The trial is currently recruiting and welcomes children of all genders between the ages of 0 to 17.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pediatric patients, newly diagnosed with Kawasaki disease
- • Pediatric patients, newly diagnosed with Vasculitis
- • Pediatric patients, newly diagnosed with SARS-CoV-2 infection
- • Pediatric patients, newly diagnosed with febrile virosis
- • Pediatric patients with inflammatory diseases with systemic involvement
- Exclusion Criteria:
- • None
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Bologna, , Italy
Carpi, Modena, Italy
Modena, , Italy
Roma, , Italy
Torino, , Italy
Patients applied
Trial Officials
Marianna Fabi, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported